Palliative care delivery according to age in 12,000 women with metastatic breast cancer: Analysis in the multicentre ESME-MBC cohort 2008-2016.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
09 2020
Historique:
received: 05 06 2020
accepted: 06 07 2020
pubmed: 18 8 2020
medline: 9 2 2021
entrez: 18 8 2020
Statut: ppublish

Résumé

Patients with metastatic breast cancer (MBC) often require inpatient palliative care (IPC). However, mounting evidence suggests age-related disparities in palliative care delivery. This study aimed to assess the cumulative incidence function (CIF) of IPC delivery, as well as the influence of age. The national ESME (Epidemio-Strategy-Medical-Economical)-MBC cohort includes consecutive MBC patients treated in 18 French Comprehensive Cancer Centres. ICD-10 palliative care coding was used for IPC identification. Our analysis included 12,375 patients, 5093 (41.2%) of whom were aged 65 or over. The median follow-up was 41.5 months (95% confidence interval [CI], 40.5-42.5). The CIF of IPC was 10.3% (95% CI, 10.2-10.4) and 24.8% (95% CI, 24.7-24.8) at 2 and 8 years, respectively. At 2 years, among triple-negative patients, young patients (<65 yo) had a higher CIF of IPC than older patients after adjusting for cancer characteristics, centre and period (65+/<65: β = -0.05; 95% CI, -0.08 to -0.01). Among other tumour sub-types, older patients received short-term IPC more frequently than young patients (65+/<65: β = 0.02; 95% CI, 0.01 to 0.03). At 8 years, outside large centres, IPC was delivered less frequently to older patients adjusted to cancer characteristics and period (65+/<65: β = -0.03; 95% CI, -0.06 to -0.01). We found a relatively low CIF of IPC and that age influenced IPC delivery. Young triple-negative and older non-triple-negative patients needed more short-term IPCs. Older patients diagnosed outside large centres received less long-term IPC. These findings highlight the need for a wider implementation of IPC facilities and for more age-specific interventions.

Identifiants

pubmed: 32805641
pii: S0959-8049(20)30390-7
doi: 10.1016/j.ejca.2020.07.007
pii:
doi:

Types de publication

Historical Article Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

240-249

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Matthieu Frasca (M)

University of Bordeaux, Inserm, Bordeaux Population Health Research Centre, Epicene Team, UMR 1219, 33000, Bordeaux, France; Department of Palliative Medicine, CHU Bordeaux, 33000, Bordeaux, France. Electronic address: matthieu.frasca@u-bordeaux.fr.

Camille Sabathe (C)

University of Bordeaux, Inserm, Bordeaux Population Health Research Centre, Biostatistic Team, UMR 1219, 33000, Bordeaux, France.

Suzette Delaloge (S)

Department of Medical Oncology, Gustave Roussy, 114 Rue Edouard Vaillant, 94800, Villejuif, France.

Angeline Galvin (A)

University of Bordeaux, Inserm, Bordeaux Population Health Research Centre, Epicene Team, UMR 1219, 33000, Bordeaux, France.

Anne Patsouris (A)

Department of Medical Oncology, Institut de Cancérologie de L'Ouest - Paul Papin, 49933, Angers, France.

Christelle Levy (C)

Department of Medical Oncology, Centre François Baclesse, 3, Avenue Du Général Harris, 14076, Caen, France.

Marie A Mouret-Reynier (MA)

Department of Medical Oncology, Centre Jean Perrin, 58 Rue Montalembert, 63011, Clermont-Ferrand, France.

Isabelle Desmoulins (I)

Department of Medical Oncology, Centre Georges-Francois Leclerc, 1 Rue Professeur Marion, 21079, Dijon, France.

Laurence Vanlemmens (L)

Department of Medical Oncology, Centre Oscar Lambret, 3 Rue Frédéric Combemale, 59000, Lille, France.

Thomas Bachelot (T)

Department of Medical Oncology, Centre Léon Bérard, 28 Promenade Léa et Napoléon Bullukian, 69008, Lyon, France.

Anthony Goncalves (A)

Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard de Sainte-Marguerite, 13009, Marseille, France.

Virginie Perotin (V)

Department of Palliative Medicine, Institut Du Cancer de Montpellier, 208 Rue des Apothicaires, 34298, Montpellier, France.

Lionel Uwer (L)

Department of Medical Oncology, Institut de Cancérologie de Lorraine, 6 Avenue de Bourgogne, 54519 Vandoeuvre-lès-Nancy, France.

Jean S Frenel (JS)

Department of Medical Oncology, Institut de Cancérologie de L'Ouest - René Gauducheau, Boulevard Professeur Jacques Monod, 44805, Nantes, France.

Jean M Ferrero (JM)

Department of Medical Oncology, Centre Antoine Lacassagne, 33 Avenue de Valambrose, 06189, Nice, France.

Carole Bouleuc (C)

Department of Medical Oncology, Institut Curie, 26 Rue D'Ulm; 75005, Paris & Saint-Cloud, France.

Jean C Eymard (JC)

Department of Medical Oncology, Institut de Cancérologie Jean-Godinot, 1 Rue de Général Koenig, 51100, Reims, France.

Véronique Dieras (V)

Department of Medical Oncology, Centre Eugène Marquis, Avenue de La Bataille Flandres-Dunkerque, 35000, Rennes, France.

Marianne Leheurteur (M)

Department of Medical Oncology, Centre Henri Becquerel, Rue D'Amiens, 76000, Rouen, France.

Thierry Petit (T)

Department of Medical Oncology, Centre Paul Strauss, 3 Rue de La Porte de L'Hôpital, 67000, Strasbourg, France.

Florence Dalenc (F)

Department of Medical Oncology, Institut Claudius Regaud - IUCT Oncopole, 1 Avenue Irène-Joliot-Curie, 31059, Toulouse, France.

Anne Jaffre (A)

Department of Medical Information, Institut Bergonie, Comprehensive Cancer Centre, 33000, Bordeaux, France.

Michaël Chevrot (M)

Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.

Coralie Courtinard (C)

Department of Research and Development, R&D Unicancer, 101 Rue de Tolbiac, 75654, Paris, France.

Simone Mathoulin-Pelissier (S)

University of Bordeaux, Inserm, Bordeaux Population Health Research Centre, Epicene Team, UMR 1219, 33000, Bordeaux, France; INSERM CIC1401, Institut Bergonie, Comprehensive Cancer Centre, 33000, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH